Virtual Press Room

The Virtual Press Room is a courtesy for corporate and institutional public relations professionals. Publication of material on this page does not constitute an endorsement by ASCO of any product or claim.

For information about how to submit a press release to the Virtual Press Room, visit the For PR Professionals page.

2015 ASCO Annual Meeting

Amgen
Amgen Initiated Phase 3 Study Evaluating Once-Weekly Kyprolis® (Carfilzomib) in Patients with Relapsed and Refractory Multiple Myeloma
Amgen Presents Phase 3 Data at ASCO Showing Prolia® (Denosumab) Significantly Reduced Bone Fractures in Breast Cancer Patients Receiving Aromatase Inhibitors

Argos Therapeutics
Argos Therapeutics Provides Update on Enrollment Progress for Ongoing Pivotal Phase 3 ADAPT Clinical Trial

Arno Therapeutics
Arno Therapeutics Announces Data Validating Continued Onapristone and Companion Diagnostic Development at ASCO Annual Meeting 2015

Boehringer Ingelheim
ASCO 2015: Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial in patients with previously treated advanced squamous cell carcinoma of the lung
Boehringer Ingelheim Showcases Expanding Presence in Lung Cancer at ASCO 2015 With New Data Including Presentation of Afatinib Overall Survival Results for Squamous Cell Carcinoma of the Lung

Caris Life Sciences
Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 
Caris Life Sciences Presents New Tumor Profiling Research Providing Insights into the Clinical Benefit of Targeted Therapies for Colorectal Cancer Treatment-Resistant Subgroups
Caris Molecular Intelligence Multi-Platform Tumor Profiling Facilitates Comparisons between Tumors that Share Histological Features ​
Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors  
Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 

Eisai
Eisai to Present New Data on Several Oncology Compounds at ASCO 2015 

Fox Chase Cancer Center
African Americans Prone To Display Negative Perceptions of Cancer-Related Clinical Trials
New Targeted Treatment IMMU-130 Shows Promise in Patients with Metastatic Colon Cancer
Next Generation Sequencing-Based Tumor Genomic Profiling Aids in Detecting Hereditary Variants in Cancer Risk Genes
Patient Interest, Willingness to Pay Out of Pocket Costs for Tumor Genetic Profiling Assessed by Fox Chase Researchers
Researchers Developing New Targeted and Immune Therapies for Colorectal Cancer Molecular Subtypes

Genelux Corporation
Genelux Announces Promising Data from Two Phase I Trials of GL-ONC1 in Head & Neck Cancer and Mesothelioma

Invitae
Invitae and Collaborators to Present New Data at the 2015 American Society of Clinical Oncology Annual Meeting Focusing on the Clinical Utility of Multi-Gene Panel Tests for Hereditary Breast and Ovarian Cancer

Ipsen Biopharmaceuticals
Ipsen Announces Data Presentations for Somatuline Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting 

Insight Genetics
Insight Genetics to Present New Data on Subtyping Ovarian Cancer at 2015 American Society of Clinical Oncology Annual Meeting 

Myriad Genetics
Myriad Showcases Its Pioneering Research at the 2015 ASCO Annual Meeting

New York-Presbyterian, Weill Cornell Medical College, and Columbia University College of Physicians and Surgeons
Oncologists from NewYork-Presbyterian, Weill Cornell Medical College and Columbia University College of Physicians and Surgeons Present at American Society of Clinical Oncology’s Annual Meeting

Novartis
Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma
Novartis presents new data at ASCO for Zykadia™ and combination of Tafinlar® and Mekinist® in certain NSCLC patients with unmet needs

Novocure
Novocure Announces First Analysis of Full 700 Patient Dataset from Successful Newly Diagnosed GBM Phase III Trial 

Onxeo
Onxeo Announces Final Data from Completed Phase II Trial of Validive® for the Prevention of Severe Oral Mucositis in Head and Neck Cancer Patients 

Pharmacyclics
Analysis of Phase III RESONATETM Data Shows Adherence to the Recommended 420mg Dose of IMBRUVICA® (ibrutinib) Results in Improved Efficacy Benefits in Patients with Chronic Lymphocytic Leukemia
Ibrutinib (IMBRUVICA® ) Phase Ib/II Data Show Promise in Patients with Chronic Graft-Versus-Host-Disease 

PharmaMar
PharmaMar Announces New Advances in Oncology at ASCO 2015 for its Compounds YONDELIS® and PM1183 in Small Cell Lung Cancer, Soft Tissue Sarcoma, and Mesothelioma 

PharmaMar’s investigational drug PM1183 plus doxorubicin shows remarkable activity in small cell lung cancer 

Real Endpoints
Real Endpoints’ Interactive Model Compares the Value of Different Drug Regimens in HER2+, ER-/PR- Breast Cancer

Roswell Park Cancer Institute
Biomarker Analysis Reveals Several Potential Treatment Targets in Subtype of Anal Cancer
Melanoma Rates Dramatically Increasing in Children and Young Adults​
Phase III Study Confirms Benefits of Lenalidomide Maintenance Therapy for Patients with Multiple Myeloma
Roswell Park Scientists Develop Mobile Application Software for Colon Cancer Survivors

Transgene
Transgene Announces Positive New Results Presented at ASCO from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer​

University Hospitals Case Medical Center
UH Case Medical Center Experts to Present Data at 51st ASCO Annual Meeting​

University of Alabama at Birmingham Comprehensive Cancer Center
Preliminary UAB study shows dramatic trend of cost savings in lay navigation program for cancer patients​

University of Colorado Cancer Center
ONT-380 has stage IV HER2+ breast cancer patient “worrying about normal stuff again” 
Promising trial results of brigatinib show that all next-gen ALK inhibitors may not be created equal
Study shows sexual dysfunction after gynecologic cancer treatment